NasdaqGS:MISTPharmaceuticals
Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?
Milestone Pharmaceuticals recently received U.S. Food and Drug Administration approval for CARDAMYST (etripamil) nasal spray, its first commercial product for at-home conversion of acute symptomatic paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, with retail availability targeted for early 2026.
This is the first new FDA-approved PSVT treatment in over 30 years and introduces a self-administered, out-of-hospital option for more than two million affected Americans,...